Table 4 Oral antidiabetic drug use before insulin initiation, at insulin initiation, and at 1-year follow-up
Oral antidiabetic drug | Before insulin initiation (N = 511) | At insulin initiation (N = 511) | 1-year follow-up (N = 488) |
|---|---|---|---|
No. of oral antidiabetic drugs, n (%) | |||
0 | 98 (19.2%) | 262 (51.3%) | 229 (46.9%) |
1 | 119 (23.3%) | 110 (21.5%) | 127 (26.0%) |
2 | 170 (33.3%) | 91 (17.8%) | 94 (19.3%) |
≥3 | 124 (24.3%) | 48 (9.4%) | 38 (7.8%) |
Drug class, n (%) | |||
Biguanides | 148 (29.0%) | 109 (21.3%) | 120 (24.6%) |
Sulfonylureas | 357 (69.9%) | 133 (26.0%) | 99 (20.3%) |
Glinides | 28 (5.5%) | 10 (2.0%) | 78 (16.0%) |
Thiazolidinediones | 134 (26.2%) | 80 (15.7%) | 36 (7.4%) |
α-glucosidase inhibitor | 177 (34.6%) | 107 (20.9%) | 104 (21.3%) |
Others | 5 (1.0%) | 5 (1.0%) | 0 |